- Home
- DOMH vs APVO Comparison
DOMH vs APVO Comparison
Compare DOMH & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- APVO
- Stock Information
- Founded
- DOMH 1967
- APVO 2016
- Country
- DOMH United States
- APVO United States
- Employees
- DOMH N/A
- APVO N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- APVO Health Care
- Exchange
- DOMH Nasdaq
- APVO Nasdaq
- Market Cap
- DOMH 74.9M
- APVO 5.4M
- IPO Year
- DOMH N/A
- APVO N/A
- Fundamental
- Price
- DOMH $5.39
- APVO $2.36
- Analyst Decision
- DOMH
- APVO Strong Buy
- Analyst Count
- DOMH 0
- APVO 1
- Target Price
- DOMH N/A
- APVO $296.00
- AVG Volume (30 Days)
- DOMH 1.6M
- APVO 47.0K
- Earning Date
- DOMH 05-08-2025
- APVO 05-07-2025
- Dividend Yield
- DOMH 5.66%
- APVO N/A
- EPS Growth
- DOMH N/A
- APVO N/A
- EPS
- DOMH N/A
- APVO N/A
- Revenue
- DOMH $12,589,000.00
- APVO N/A
- Revenue This Year
- DOMH N/A
- APVO N/A
- Revenue Next Year
- DOMH N/A
- APVO N/A
- P/E Ratio
- DOMH N/A
- APVO N/A
- Revenue Growth
- DOMH 1117.50
- APVO N/A
- 52 Week Low
- DOMH $0.83
- APVO $2.37
- 52 Week High
- DOMH $13.58
- APVO $209.38
- Technical
- Relative Strength Index (RSI)
- DOMH 46.01
- APVO 28.80
- Support Level
- DOMH $5.18
- APVO $3.02
- Resistance Level
- DOMH $8.55
- APVO $4.00
- Average True Range (ATR)
- DOMH 1.42
- APVO 0.27
- MACD
- DOMH -0.57
- APVO -0.03
- Stochastic Oscillator
- DOMH 7.68
- APVO 0.00
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.